An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.

Your daily dose of the clinical news you may have missed.

The USPSTF recommends that BP be checked at all prenatal visits for all pregnant persons and calls for reducing vast inequities in maternal health care.

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

Your daily dose of the clinical news you may have missed.

The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.

Jacinda Abdul-Mutakabbir, PHARMD, MPH, AAHIVP, leads a conversation on the importance of vaccination in the defense and protection against viral infections, such as the flu.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, shares her thoughts on the changing perception of influenza and influenza vaccination post the COVID-19 pandemic.

Overscheduled and undertrained, primary care clinicians shoulder a significant portion of the US wound care burden. Author Nima Ahmadi offers a technology-based solution.

Results from a new study show that older adults with untreated hypertension had a 42% increased risk of dementia vs healthy controls.

Resmetirom, a once-daily oral, thyroid hormone receptor (THR)-β selective agonist, targets key underlying NASH pathophysiology in the liver.

Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.

Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.

Your daily dose of the clinical news you may have missed.

Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.

Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).

Tina Tan, MD, FAAP, FIDSA, FPIDS, presents the background, objectives, and methods of a recent study on the efficacy and safety of nirsevimab for Respiratory Syncytial Virus (RSV) in late-preterm and term infants.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, introduce the objectives of their discussion and background information on Respiratory Syncytial Virus (RSV) and nirsevimab.

Your daily dose of the clinical news you may have missed.

Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.

Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.